Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies
Conditions:  Metastatic Malignant Female Reproductive System Neoplasm;  Platinum-Resistant Malignant Female Reproductive System Neoplasm;  Recurrent Malignant Female Reproductive System Neoplasm;  Refractory Malignant Female Reproductive System Neoplasm Interventions:  Biological: Durvalumab;  Radiation: Internal Radiation Therapy;  Biological: Tremelimumab Sponsors:  Jonsson Comprehensive Cancer Center;  National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials